International Journal of Enhanced Research in Science, Technology & Engineering
ISSN: 2319-7463, Vol. 7 Issue 11, November-2018, Impact Factor: 4.059

Eco-Toxicological Evaluation of Medicinal Heterocycles and Their Metabolites in Aquatic Ecosystems

Dr. Swati Sharma

Department of Chemistry Baba Gangadas Government Girls College Shahpura, Jaipur, Rajasthan

ABSTRACT

The global rise in pharmaceutical consumption has resulted in the continuous input of medicinal residues into aquatic environments. Among these, heterocyclic drugs—especially those containing oxygen, nitrogen, and sulfur heteroatoms—are of concern due to their persistence, bioaccumulation, and potential ecotoxicity. This study investigates the occurrence, degradation patterns, and ecological impact of selected heterocyclic pharmaceuticals and their metabolites between 2011 and 2017. Samples from surface water, wastewater effluents, and sediment were analyzed for compounds such as ciprofloxacin (N-containing quinolone), furosemide (O-containing heterocycle), and ranitidine (S- and N-containing heterocycle). Quantitative assessment employed HPLC–MS/MS techniques, while degradation kinetics were studied under natural sunlight and microbial activity. Results indicate incomplete biodegradation, with half-lives (t½) ranging from 8 to 30 days in surface waters. Bioaccumulation factors (BAFs) ranged from 120–560 L/kg, suggesting moderate bioaccumulative potential. Chronic exposure studies revealed oxidative stress and enzymatic inhibition in aquatic biota (Daphnia magna, Danio rerio). The findings emphasize the urgent need for green pharmaceutical design and improved wastewater treatment technologies.

Keywords: Heterocyclic pharmaceuticals; bioaccumulation; aquatic toxicity; environmental degradation; persistence; green chemistry; wastewater treatment; ecotoxicology; pharmaceutical residues.

INTRODUCTION

1.1 Background and Rationale

Pharmaceutical compounds are designed for therapeutic efficacy, selectivity, and metabolic stability. This inherent chemical stability—essential for ensuring the desired biological activity and long shelf life—also contributes to environmental persistence when these compounds are released into nature through human excretion, hospital effluents, manufacturing discharges, or improper disposal. Between 2011 and 2017, global attention was increasingly drawn to pharmaceutical pollution, recognized as an emerging environmental concern by the World Health Organization (WHO) and the Organisation for Economic Co-operation and Development (OECD). The OECD (2016) reported that over 60 percent of marketed pharmaceuticals contain heterocyclic structures because these molecular frameworks enhance pharmacological potency and bioavailability. Heterocycles typically feature oxygen, nitrogen, and sulfur atoms, which provide unique reactivity and pharmacological versatility but also make them resistant to microbial degradation, resulting in long-term persistence in aquatic environments.

1.2 Environmental Entry Pathways

Pharmaceutical residues generally enter aquatic systems through multiple pathways. The major sources and their estimated contributions are summarized below.

Table 1: Environmental Entry Pathways

Source	Description	Estimated Contribution (%)
Domestic sewage	Excretion of unmetabolized drugs and their conjugates	40–50
Hospital wastewater	High concentration point-source contamination	20–30
Pharmaceutical manufacturing	Direct industrial discharge	10–15
Improper disposal (households, pharmacies)	Unused or expired drugs flushed or dumped	10–20

(Data compiled from OECD (2016) and Verlicchi et al., 2015)

These continuous discharges result in low-dose, long-term exposure of aquatic systems to pharmaceutical residues. Even when some compounds degrade slowly, their steady replenishment leads to a phenomenon known as "pseudo-persistence," where the environmental concentration remains stable over time despite partial degradation.

1.3 Significance of Heterocyclic Pharmaceuticals

Heterocyclic drugs, such as ciprofloxacin (fluoroquinolone, nitrogen-containing), furosemide (oxygen-containing), ranitidine (nitrogen and sulfur-containing), and omeprazole (benzimidazole derivative), are widely prescribed worldwide. These compounds possess strong aromatic and heteroatom-containing bonds like carbon–nitrogen, carbon–sulfur, and carbon–fluorine, which provide structural stability and enhance therapeutic performance. However, this same chemical robustness also reduces their susceptibility to photolysis, hydrolysis, and microbial degradation. Traces of these drugs and their transformation products have been found in different environmental compartments. Concentrations of ciprofloxacin as high as 2 µg/L were detected in surface waters (Kümmerer, 2011), while groundwater levels of 0.1–0.5 µg/L have been reported in developing countries (Mutiyar & Mittal, 2012). Sediment and aquatic organism samples show bioaccumulation factors ranging between 100 and 500 L/kg (Chen et al., 2013). Although these values appear low, the persistence and continuous exposure can cause chronic ecological disturbances, affecting non-target aquatic organisms such as algae, daphnia, and fish.

1.4 Environmental and Ecotoxicological Implications

Between 2011 and 2017, several global monitoring programs, including the European Union Water Framework Directive (EU-WFD) and India's Central Pollution Control Board (CPCB) surveys, highlighted increasing levels of heterocyclic pharmaceutical residues in both developed and developing nations. For example, ciprofloxacin concentrations up to 1.8 µg/L were found in European rivers (Gómez et al., 2014). In India, hospital effluents from Delhi showed ranitidine and omeprazole residues exceeding 2.1 µg/L (Mutiyar & Mittal, 2012). Chronic exposure experiments revealed reduced reproduction and enzyme inhibition in Daphnia magna and liver oxidative stress in Danio rerio (Li et al., 2016). Even trace concentrations of such persistent compounds can disrupt microbial community structures, nutrient cycling, and ecosystem resilience. Moreover, metabolites formed through partial degradation may remain biologically active or even exhibit enhanced toxicity. Hydroxy-ranitidine metabolites, for instance, were found to produce stronger oxidative stress effects than the parent compound (Białk-Bielińska et al., 2017). This demonstrates that environmental risk assessments must include both parent compounds and their metabolites to understand the full toxicological impact.

LITERATURE REVIEW

Between 2011 and 2017, a significant number of environmental studies were conducted to assess the occurrence, persistence, and ecological impact of heterocyclic pharmaceuticals in aquatic environments. The growing use of medicines containing nitrogen, oxygen, and sulfur heterocycles, combined with inadequate wastewater treatment technologies, led to widespread detection of these compounds in both surface and ground waters across the globe. In 2011, Kümmerer and colleagues conducted one of the pioneering studies on the presence of fluoroquinolone antibiotics in European rivers. They reported that compounds such as ciprofloxacin and norfloxacin were frequently detected in concentrations reaching up to 1.8 µg/L. The study emphasized that these drugs showed poor biodegradability due to the stability of their carbon–fluorine and carbon–nitrogen bonds, leading to their persistence even after conventional wastewater treatment processes. This finding marked an early warning regarding the environmental durability of heterocyclic pharmaceuticals and their potential for accumulation in aquatic ecosystems. The following year, in 2012, Mutiyar and Mittal carried out an important investigation on hospital wastewater in India, highlighting the presence of sulfur-containing heterocyclic drugs such as ranitidine and omeprazole in concentrations exceeding 2.1 µg/L. The study revealed that Indian hospital effluents often lacked advanced treatment stages, allowing pharmaceutical residues to enter municipal drains and eventually surface waters.

These findings provided evidence that developing countries, with growing healthcare demands and limited wastewater infrastructure, face a particularly serious challenge in controlling pharmaceutical pollution. By 2013, research attention had shifted toward understanding the bioaccumulation of these compounds in aquatic organisms. Chen et al. (2013) examined the bioconcentration potential of ciprofloxacin and related fluoroquinolones in aquatic species such as fish and algae. The study found bioaccumulation factors (BAFs) ranging between 100 and 400 L/kg, suggesting that these drugs are moderately bioaccumulative and capable of entering the food web. Such findings raised concern about chronic exposure risks for higher trophic organisms, including fish-eating birds and mammals. In 2014, Gómez and collaborators investigated the environmental fate of furosemide, an oxygen-containing heterocyclic diuretic, focusing on its photolytic degradation under natural sunlight. Their study demonstrated that only 40 percent of the compound degraded after ten days of sunlight exposure, highlighting its limited photolytic breakdown capacity. This reinforced the observation that many heterocyclic compounds are chemically stable in natural aquatic conditions, contributing to their long-term persistence in surface waters and sediments. Verlicchi et al. (2015) expanded this understanding by assessing the efficiency of various wastewater treatment technologies. Their comparative analysis revealed that ozonation and advanced oxidation processes could remove between 60 and 80 percent of pharmaceuticals, whereas conventional biological treatment achieved less than 30 percent removal efficiency. This gap illustrated that standard

treatment methods are largely ineffective against heterocyclic compounds, as these structures resist microbial degradation and remain stable under aerobic conditions. Consequently, treated effluents still contained measurable concentrations of pharmaceuticals, contributing to continuous environmental exposure. In 2016, Li and colleagues conducted a series of chronic toxicity experiments using the aquatic organism Daphnia magna to assess the sub-lethal effects of heterocyclic drug exposure. The study showed that even at low concentrations, pharmaceuticals such as ciprofloxacin and ranitidine caused reduced reproduction rates and significant enzyme inhibition in the exposed organisms. These biological effects confirmed that pharmaceutical residues could exert ecological pressure on non-target aquatic species by interfering with their metabolic and reproductive functions, ultimately threatening ecosystem balance.

By 2017, researchers began to focus more on the environmental behavior and toxicity of pharmaceutical metabolites. Białk-Bielińska et al. (2017) analyzed hydroxy and desmethyl metabolites derived from common heterocyclic drugs and found that these transformation products often displayed higher toxicity than their parent compounds. This was attributed to the presence of reactive functional groups formed during partial degradation processes, which increased their affinity for biological receptors. The study concluded that environmental monitoring should not be limited to parent pharmaceutical compounds but must also include their metabolites to provide a more accurate picture of ecological risk. The cumulative evidence from 2011 to 2017 reveals a consistent global trend. Heterocyclic pharmaceuticals exhibit high chemical stability, low biodegradation rates, and a notable capacity for bioaccumulation. Despite technological advancements in wastewater treatment, a significant proportion of these compounds persist post-treatment, entering surface waters, sediments, and biota. This persistence leads to chronic environmental exposure and potential long-term ecological effects. The reviewed literature underscores the urgent need for more effective removal technologies, green pharmaceutical synthesis approaches, and comprehensive environmental policies aimed at mitigating the eco-toxicological impacts of medicinal heterocycles in aquatic ecosystems.

METHODOLOGY

The present study was designed to evaluate the environmental persistence, degradation behavior, and bioaccumulation potential of selected heterocyclic pharmaceutical compounds and their metabolites in aquatic ecosystems. The methodology was developed to ensure that sampling, analytical, and experimental procedures were conducted with high precision, reproducibility, and environmental relevance. The approach integrates field sampling, laboratory-based chemical analysis, and ecotoxicological assessment to obtain a comprehensive understanding of the environmental fate of these compounds.

3.1 Sampling Locations

Water and sediment samples were collected from different environmental settings representing both developed and developing countries to ensure a comparative global perspective. The rivers selected for this study included the Yamuna River in India, the Rhine River in Germany, and the Thames River in the United Kingdom. These rivers were chosen because they receive substantial urban and industrial discharges, making them ideal indicators of pharmaceutical contamination in aquatic environments. In addition to river samples, effluent samples were obtained from hospital wastewater outlets and municipal wastewater treatment plants located near urban centers. These sources were selected because hospital effluents typically contain high concentrations of active pharmaceutical ingredients and metabolites that enter the aquatic system through drainage networks. Sampling from both inflow and outflow points of the treatment plants helped in evaluating removal efficiency during the wastewater treatment process.

Sediment samples were also collected from each river site to assess the long-term accumulation of heterocyclic compounds in benthic zones. Samples were taken from the upper five centimeters of the riverbed using a stainless-steel sediment core sampler. This depth was selected because the top sediment layer represents the most biologically active and chemically interactive region, where organic pollutants are likely to adsorb and persist over time. All samples were collected in pre-cleaned amber glass bottles, transported on ice at 4°C, and processed within 24 hours to minimize chemical degradation prior to analysis.

3.2 Analytical Techniques

The quantification and identification of pharmaceutical compounds and their metabolites were carried out using advanced chromatographic and spectrometric techniques. High-performance liquid chromatography coupled with tandem mass spectrometry (HPLC–MS/MS) was employed as the primary analytical tool for quantitative determination. The instrument used was the Agilent 6460 Triple Quadrupole Mass Spectrometer, operated under electrospray ionization in both positive and negative modes to cover a wide range of heterocyclic compounds. The detection limit of the method was optimized to 0.01 micrograms per liter (µg/L), ensuring high sensitivity for trace-level detection in environmental samples. Recovery rates were maintained above 90 percent, verified through the use of matrix-matched calibration standards and spiked recovery tests. The target compounds analyzed included ciprofloxacin, ranitidine, and furosemide—representing nitrogen-, sulfur-, and oxygen-containing heterocycles respectively. Metabolite identification was performed using liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (LC–QTOF-MS). This high-resolution analytical approach enabled accurate mass determination and

isotopic pattern analysis for the confirmation of transformation products such as hydroxy and desmethyl derivatives. Internal standards were used for quality control to ensure consistency in retention times and ionization efficiency throughout the analytical process. Data processing and quantification were carried out using Agilent MassHunter software, with calibration curves constructed over a concentration range of 0.01 to 10 µg/L to achieve linearity with R^2 values greater than 0.995.

3.3 Degradation and Bioaccumulation Tests

To assess the environmental stability and degradation behavior of the selected heterocyclic compounds, both photolysis and biodegradation experiments were conducted under controlled laboratory conditions. Photolysis experiments were performed by exposing aqueous solutions of the target compounds to natural sunlight at an average temperature of 25°C. The test samples were placed in quartz beakers to allow the full penetration of ultraviolet and visible light. Control samples were kept in the dark to differentiate between photolytic and non-photolytic losses. Aliquots were withdrawn periodically over a 10-day period, and concentration changes were analyzed using HPLC–MS/MS to calculate degradation rates and half-lives. Biodegradation studies followed the OECD 301B CO_2 evolution test protocol, which measures the mineralization of organic carbon to carbon dioxide as an indicator of microbial activity. The tests were carried out using activated sludge obtained from a municipal wastewater treatment plant. Each test system consisted of a 500 mL glass flask containing 250 mL of mineral medium inoculated with the sludge and dosed with a known concentration of the pharmaceutical compound.

The flasks were maintained at 25°C with continuous aeration for 28 days. Carbon dioxide evolution was measured using barium hydroxide traps, and biodegradation percentages were calculated based on theoretical CO_2 generation. Bioaccumulation potential was evaluated through fish exposure studies using Danio rerio (zebrafish) as the test species, following OECD guideline 305. Fish were exposed to sub-lethal concentrations of each compound in aerated aquaria for 28 days. Tissue samples were collected at regular intervals to measure the concentration of pharmaceuticals in fish muscle and liver using LC–MS/MS analysis. The bioaccumulation factor (BAF) was calculated as the ratio of the concentration in fish tissue to that in the surrounding water at steady state. These data provided an understanding of how heterocyclic drugs and their metabolites partition between water and biological systems, offering insight into potential food chain transfer. All experimental procedures were conducted under strict quality control and assurance standards, including the use of procedural blanks, duplicate samples, and certified reference materials. The combination of chemical analysis, photolytic degradation, biodegradation testing, and bioaccumulation studies allowed for a comprehensive evaluation of the environmental fate and eco-toxicological characteristics of heterocyclic pharmaceuticals and their metabolites.

RESULTS AND DATA ANALYSIS

The results of this study provide a comprehensive view of the occurrence, persistence, and biological effects of selected heterocyclic pharmaceuticals in aquatic environments. The analysis focused on three representative compounds: ciprofloxacin (a nitrogen-containing fluoroquinolone), ranitidine (a sulfur- and nitrogen-containing antihistamine), and furosemide (an oxygen-containing diuretic). The data obtained from environmental sampling and laboratory experiments between 2011 and 2017 reveal significant insights into the environmental distribution, degradation behavior, and ecotoxicological implications of these compounds.

Table 2. Concentration of Selected Heterocyclic Drugs (µg/L) in Aquatic Samples

Compound	Surface Water (µg/L)	Effluent (µg/L)	Sediment (µg/kg)	Half-Life (days)	Bioaccumulation Factor (L/kg)
Ciprofloxacin	0.45	1.9	230	18	540
Ranitidine	0.38	2.1	180	12	290
Furosemide	0.25	1.2	90	9	120

The data presented in Table 1 indicate a clear pattern of elevated pharmaceutical concentrations in wastewater effluents compared to surface water samples. Effluent concentrations of ciprofloxacin, ranitidine, and furosemide were found to be approximately four to six times higher than those detected in river water, suggesting incomplete removal during wastewater treatment. This finding highlights the limitations of conventional treatment processes in effectively degrading complex heterocyclic compounds. Among the three compounds, ciprofloxacin exhibited the highest environmental persistence and bioaccumulation potential. Its half-life of approximately 18 days and bioaccumulation factor of 540 L/kg indicate strong resistance to both microbial degradation and photolytic breakdown. This persistence can be attributed to the stability of the carbon–fluorine and nitrogen–heterocyclic bonds present in its structure, which makes it less susceptible to environmental transformation processes. Ranitidine, though slightly more degradable with a half-life of 12 days, was found at the highest effluent concentration (2.1 µg/L). This is likely due to its widespread medical use and the incomplete removal of both parent compounds and metabolites during biological treatment. Furosemide, on the other hand, exhibited relatively lower environmental concentrations and a shorter half-life,

suggesting it is somewhat more susceptible to degradation processes, possibly due to its oxygenated heterocyclic structure which enhances photolytic reactivity. Sediment concentrations of all three compounds confirm their tendency to adsorb onto particulate matter, with ciprofloxacin showing the greatest sediment binding at 230 µg/kg. This indicates the potential for long-term storage of these drugs in benthic environments, where they may persist even after concentrations in the overlying water decrease. Such sediment adsorption presents an additional ecological risk, as benthic organisms can be exposed chronically to these residues, leading to potential food-chain transfer.

Table 3. Toxicological Effects on Aquatic Biota

Species	Compound	LC_{50} (mg/L)	Observed Effect	Enzyme Inhibition (%)
Daphnia magna	Ciprofloxacin	14.2	Reduced reproduction	35
Danio rerio (Zebrafish)	Ranitidine	16.8	Liver oxidative stress	28
Chlorella vulgaris (Algae)	Furosemide	22.4	Reduced photosynthesis	18

The toxicity assessment data summarized in Table 2 illustrate the varying degrees of biological impact caused by the selected heterocyclic pharmaceuticals on aquatic organisms. Ciprofloxacin demonstrated the highest toxicity among the tested compounds, with an LC_{50} (lethal concentration for 50 percent of the population) value of 14.2 mg/L for Daphnia magna. This value, coupled with an enzyme inhibition rate of 35 percent, indicates significant sub-lethal effects such as reduced reproduction and metabolic disruption. The high toxicity of ciprofloxacin correlates strongly with its environmental persistence and elevated bioaccumulation factor observed in Table 1, suggesting that long-term exposure could have severe ecological consequences for aquatic food webs. Ranitidine showed moderate toxicity toward Danio rerio (zebrafish), with an LC_{50} value of 16.8 mg/L.

The primary physiological effect observed was liver oxidative stress, evidenced by an increase in lipid peroxidation and reduction in antioxidant enzyme activity. These effects are indicative of oxidative damage caused by reactive metabolites or stress responses triggered by prolonged exposure to pharmaceutical contaminants. The 28 percent enzyme inhibition further supports the notion that even at non-lethal concentrations, ranitidine can interfere with critical metabolic pathways in aquatic organisms. Furosemide exhibited comparatively lower toxicity toward the tested algae species Chlorella vulgaris, with an LC_{50} value of 22.4 mg/L and an enzyme inhibition of 18 percent. Although less toxic than ciprofloxacin or ranitidine, its impact on algal photosynthetic activity is noteworthy, as primary producers like algae form the base of the aquatic food chain. Inhibition of photosynthesis reduces oxygen production and nutrient cycling, indirectly affecting higher trophic levels. Overall, the toxicity data reveal a clear trend linking the chemical stability and persistence of heterocyclic pharmaceuticals with their potential to cause chronic ecological harm. Even when the concentrations detected in natural waters are below acute toxicity thresholds, long-term exposure can lead to sub-lethal physiological changes in aquatic organisms. These changes may not cause immediate mortality but can alter reproduction, growth, and metabolic efficiency, leading to cumulative ecological stress over time.

Comparative Analysis and Overall Interpretation

Combining the data from both tables, it becomes evident that the persistence and toxicity of heterocyclic pharmaceuticals are closely related to their chemical structures and physicochemical properties. Compounds containing nitrogen and fluorine atoms, such as ciprofloxacin, are the most stable and environmentally persistent, showing strong adsorption to sediments and a high tendency to bioaccumulate in aquatic organisms. Compounds with sulfur or oxygen atoms, such as ranitidine and furosemide, show moderate persistence but still pose significant ecological threats due to their widespread use and continual environmental discharge. The findings confirm that conventional wastewater treatment technologies are inadequate in eliminating these compounds, leading to their consistent detection in effluents and surface waters. The results also suggest that sediment compartments act as long-term reservoirs for these contaminants, allowing slow release into the water column and sustained exposure for aquatic organisms. The toxicity results reinforce the need for stricter environmental regulations on pharmaceutical effluents and the development of advanced treatment technologies such as ozonation, photocatalysis, or activated carbon filtration. Additionally, promoting green chemistry approaches in drug synthesis—focusing on molecular designs that enhance biodegradability without compromising therapeutic efficiency—can significantly reduce the ecological footprint of medicinal heterocycles.

DISCUSSION

The results of this study demonstrate a strong correlation between the structural characteristics of heterocyclic pharmaceuticals and their eco-toxicological impact on aquatic ecosystems. The molecular architecture of these compounds, particularly the presence of nitrogen, sulfur, and fluorine atoms within aromatic heterocycles, contributes significantly to their chemical stability and persistence. Nitrogen and fluorine bonds are among the most stable in organic chemistry, and their presence in compounds such as ciprofloxacin and ranitidine leads to reduced susceptibility

to hydrolysis, photolysis, and microbial degradation. This structural stability ensures that once these pharmaceuticals enter aquatic systems, they remain intact for extended periods, leading to continuous exposure of aquatic organisms to trace-level contaminants. Another critical factor influencing environmental behavior is the polarity of these compounds. The polar functional groups found in many heterocyclic drugs enhance their solubility in water, thereby increasing their bioavailability to aquatic organisms. This facilitates uptake through gills or cell membranes and can lead to bioaccumulation in tissues. Once inside an organism, these compounds may interact with enzymes or disrupt normal physiological functions. The findings of this study support earlier observations that lipophilicity, molecular weight, and polarity collectively determine the extent of bioaccumulation and toxicity. The study also highlights the complexity of pharmaceutical degradation pathways in the environment. Metabolites formed through biotic and abiotic transformations are not necessarily less harmful than their parent compounds. For instance, hydroxy-ranitidine, a metabolite formed during oxidation, has been reported to possess equal or even higher toxicity than ranitidine itself. This occurs because metabolic transformation may create reactive intermediates or alter functional groups in ways that increase biological activity.

The presence of such toxic metabolites complicates environmental risk assessments, as monitoring only parent compounds can lead to underestimation of total ecological impact. Although photolysis and biodegradation processes contribute to the partial removal of heterocyclic pharmaceuticals, their effectiveness remains limited. The half-lives observed in this study, ranging from 8 to 30 days, indicate that these compounds persist long enough to create chronic exposure scenarios in aquatic systems. In urbanized regions where pharmaceutical usage is high, constant discharge from households, hospitals, and manufacturing facilities replenishes these compounds faster than they can degrade, maintaining their steady-state concentration in water bodies. Conventional wastewater treatment systems, such as those employing activated sludge or simple aeration processes, are inadequate for removing heterocyclic pharmaceuticals effectively. These systems are primarily designed to reduce organic load and pathogens, not chemically stable micropollutants. As a result, effluents from treatment plants still contain detectable levels of pharmaceutical residues, which ultimately enter rivers, lakes, and coastal waters.

Studies have shown that advanced oxidation processes (AOPs), including ozonation, photocatalysis, and Fenton's reagent treatments, achieve better removal efficiencies by generating highly reactive hydroxyl radicals capable of breaking down complex molecular structures. However, these processes are energy-intensive and costly, limiting their widespread adoption, especially in developing nations. The findings of this study emphasize the urgent need for integrated approaches that combine technological, regulatory, and scientific interventions. Improved wastewater management systems, source reduction strategies, and environmentally benign drug design are all essential to mitigate the environmental risks associated with heterocyclic pharmaceuticals. Moreover, monitoring programs must include both parent compounds and metabolites to gain a realistic understanding of pharmaceutical pollution and its long-term effects on aquatic ecosystems.

CONCLUSION

The present study confirms that heterocyclic medicinal compounds and their metabolites represent a substantial eco-toxicological threat to aquatic environments. Their unique structural composition, which contributes to therapeutic effectiveness in humans, also results in high chemical persistence and limited biodegradability in nature. These compounds resist degradation by conventional biological and photolytic processes, allowing them to remain in aquatic systems for extended periods. Once introduced into the environment, they can accumulate in sediments and aquatic organisms, leading to bioaccumulation and potential biomagnification through the food web.

The findings further indicate that chronic exposure to even low concentrations of these compounds can cause sub-lethal biological effects such as oxidative stress, reproductive inhibition, and enzyme disruption in aquatic species. These physiological effects, although not immediately fatal, can impair ecosystem health and biodiversity over time. The results therefore underline the need for continuous monitoring of pharmaceutical residues and the inclusion of metabolite analysis in environmental risk assessments. To reduce the environmental burden of medicinal heterocycles, a multifaceted approach is necessary.

Implementing green chemistry principles in pharmaceutical synthesis can play a vital role by promoting the development of biodegradable drug analogues that retain therapeutic efficacy but degrade safely after use. Additionally, the establishment of zero-liquid-discharge systems in pharmaceutical manufacturing plants would ensure that no untreated wastewater is released into natural water bodies. Equally important are public awareness initiatives and pharmaceutical take-back programs that prevent improper disposal of unused or expired medications.

In conclusion, safeguarding aquatic ecosystems from pharmaceutical contamination requires a collaborative effort involving scientists, policymakers, industry stakeholders, and the public. Sustainable production and responsible consumption of pharmaceuticals, combined with advanced treatment technologies, can significantly reduce the environmental persistence of heterocyclic drugs and their metabolites. Such measures will contribute to maintaining ecological balance, protecting aqua

REFERENCES

[1]. Kümmerer, K. (2011). Pharmaceuticals in the Environment: Sources, Fate, Effects and Risks. Springer-Verlag, Berlin Heidelberg.
[2]. Mutiyar, P. K., & Mittal, A. K. (2012). Occurrences and fate of pharmaceuticals in Indian aquatic systems. Environmental Monitoring and Assessment, 184(9), 5099–5123.
[3]. Chen, H., Gao, B., & Li, H. (2013). Environmental fate and bioaccumulation of ciprofloxacin in aquatic systems. Environmental Science and Pollution Research, 20(7), 4306–4313.
[4]. Gómez, M. J., Bueno, M. J. M., Lacorte, S., Fernández-Alba, A. R. (2014). Pilot survey monitoring pharmaceuticals and personal care products in Spanish rivers and wastewaters. Chemosphere, 93(2), 1076–1087.
[5]. Verlicchi, P., Al Aukidy, M., & Zambello, E. (2015). What have we learned from worldwide experiences on the management and treatment of hospital effluent?—An overview and a discussion on perspectives. Science of the Total Environment, 514, 467–491.
[6]. Li, Z., He, Y., & Ma, Y. (2016). Chronic toxicity of pharmaceuticals on Daphnia magna: A case study on ciprofloxacin and ibuprofen. Environmental Toxicology and Chemistry, 35(4), 938–946.
[7]. Białk-Bielińska, A., Stolte, S., Arning, J., Uebers, U., & Matzke, M. (2017). Transformation products and toxicity of pharmaceuticals in the aquatic environment. Chemosphere, 182, 501–512.
[8]. OECD. (2016). Pharmaceutical Residues in Freshwater: Hazards and Policy Responses. Organisation for Economic Co-operation and Development (OECD) Publishing, Paris.
[9]. aus der Beek, T., Weber, F.-A., Bergmann, A., Hickmann, S., Ebert, I., Hein, A., & Küster, A. (2016). Pharmaceuticals in the environment—Global occurrences and perspectives. Environmental Toxicology and Chemistry, 35(4), 823–835.
[10]. Fent, K., Weston, A. A., & Caminada, D. (2006). Ecotoxicology of human pharmaceuticals. Aquatic Toxicology, 76(2), 122–159.
[11]. Caliman, F. A., & Gavrilescu, M. (2009). Pharmaceuticals, personal care products and endocrine-disrupting agents in the environment—A review. Clean – Soil, Air, Water, 37(4–5), 277–303.
[12]. Ternes, T. A. (1998). Occurrence of drugs in German sewage treatment plants and rivers. Water Research, 32(11), 3245–3260.
[13]. Lin, A. Y. C., & Tsai, Y. T. (2009). Occurrence of pharmaceuticals in Taiwan's surface waters: Impact of waste streams from hospitals and pharmaceutical production facilities. Science of the Total Environment, 407(12), 3793–3802.
[14]. Santos, L. H. M. L. M., Araújo, A. N., Fachini, A., Pena, A., Delerue-Matos, C., & Montenegro, M. C. B. S. M. (2010). Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment. Journal of Hazardous Materials, 175(1–3), 45–95.
[15]. Larsson, D. G. J., de Pedro, C., & Paxeus, N. (2007). Effluent from drug manufactures contains extremely high levels of pharmaceuticals. Journal of Hazardous Materials, 148(3), 751–755.
[16]. Kot-Wasik, A., Dębska, J., & Namieśnik, J. (2007). Analytical techniques in studies of the environmental fate of pharmaceuticals and personal-care products. TrAC Trends in Analytical Chemistry, 26(6), 557–568.
[17]. Andreozzi, R., Raffaele, M., & Nicklas, P. (2003). Pharmaceuticals in STP effluents and their solar photodegradation in aquatic environment. Chemosphere, 50(10), 1319–1330.
[18]. Jones, O. A. H., Voulvoulis, N., & Lester, J. N. (2002). Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Research, 36(20), 5013–5022.
[19]. Michael, I., Rizzo, L., McArdell, C. S., Manaia, C. M., Merlin, C., Schwartz, T., Dagot, C., & Fatta-Kassinos, D. (2013). Urban wastewater treatment plants as hotspots for antibiotic resistant bacteria and genes spread into the environment: A review. Science of the Total Environment, 447, 345–360.
[20]. Ghosh, S., & LaPara, T. M. (2007). The effects of subtherapeutic antibiotic use in farm animals on the proliferation and persistence of antibiotic resistance in the environment. Current Opinion in Microbiology, 10(3), 234–238.
[21]. Gros, M., Petrovic, M., & Barceló, D. (2007). Multi-residue analytical methods using LC–tandem MS for the determination of pharmaceuticals in environmental and wastewater samples. Analytical and Bioanalytical Chemistry, 387(4), 1287–1298.
[22]. Kümmerer, K. (2009). The presence of pharmaceuticals in the environment due to human use – Present knowledge and future challenges. Journal of Environmental Management, 90(8), 2354–2366.
[23]. Sui, Q., Huang, J., Deng, S., Yu, G., & Fan, Q. (2010). Occurrence and removal of pharmaceuticals, caffeine, and DEET in wastewater treatment plants of Beijing, China. Water Research, 44(2), 417–426.
[24]. Vieno, N. M., Tuhkanen, T., & Kronberg, L. (2007). Elimination of pharmaceuticals in sewage treatment plants in Finland. Water Research, 41(5), 1001–1012.
[25]. Zwiener, C., & Frimmel, F. H. (2003). Short-term tests with a pilot sewage plant and biofilm reactors for the biological degradation of the pharmaceutical compounds clofibric acid and ibuprofen. Science of the Total Environment, 309(1–3), 201–211.
[26]. Huerta-Fontela, M., Galceran, M. T., & Ventura, F. (2011). Occurrence and removal of pharmaceuticals and hormones through drinking water treatment. Water Research, 45(3), 1432–1442.

[27]. Paíga, P., Santos, L. H. M. L. M., Ramos, S., Jorge, S., Silva, J. G., Delerue-Matos, C. (2016). Presence of pharmaceuticals in the Lis river (Portugal): Sources, fate, and seasonal variation. Environmental Monitoring and Assessment, 188(4), 195.
[28]. Wang, Z., Yin, X., & Hu, B. (2015). Photodegradation of ranitidine in aqueous solutions under simulated sunlight. Environmental Science and Pollution Research, 22(15), 11864–11871.
[29]. Nikolaou, A., Meric, S., & Fatta, D. (2007). Occurrence patterns of pharmaceuticals in water and wastewater environments. Analytical and Bioanalytical Chemistry, 387(4), 1225–1234.
[30]. Daughton, C. G., & Ternes, T. A. (1999). Pharmaceuticals and personal care products in the environment: Agents of subtle change? Environmental Health Perspectives, 107(Suppl 6), 907–938.